Quintiles Library

promo_digital_graphs
Featured Case Study

Synchronized operations, quality results
Read more about how we can work with you to deliver reliable data for complex clinical...
Show Filters
Press Release
RESEARCH TRIANGLE PARK, N.C. – August 28, 2015 – Quintiles CEO Tom Pike will present at the UBS Best of Americas 2015 Conference on Friday, September 11, 2015 in London at the UBS offices. The Quintiles presentation will begin at 9:00 a.m. GMT (4:00 a.m. EDT). Investors may access a live audio webcast of the presentation on the Quintiles’ investor relations website at www.quintiles.com/investors.  An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest...
Read More
Fact Sheet
随着医疗保健市场的完善以及成本的增加,中国的医疗体系正在不断 演变,成本控制变得至关重要。支付方对证明新药价值的要求愈发强...
Read More
Video
Certain clinical trial designs are more palatable to pediatric patients and their families than others. Here, Dr. Cynthia Jackson describes ways to design more patient-centric trials that can help improve recruitment and retention by better meeting the needs of individual patients and their...
Case Study
Read more about how we can work with you to deliver reliable data for complex clinical...
Read More
Case Study
Learn how we worked with an emerging virtual company on a complex protocol, and ultimately became their sole provider across their entire...
Read More
Fact Sheet
Early clinical development of biosimilars demands an agile and efficient Phase I solution. These studies can require hundreds of volunteers and several site visits under very short timelines. Minimizing operational costs can be a challenge because many low-cost geographies lack the medical and transportation infrastructure necessary to support the rapid recruitment of a large volume of volunteers. Data collection needs to be timely and accurate to meet the expectations of both scientific stakeholders and regulatory agencies alike. And ideally, studies should be conducted within a country with regulatory processes that support biosimilars development. How do you meet these demands without sacrificing cost or quality? Quintiles is expanding Phase I operations into Central Europe with...
Read More
Case Study
Read about how we worked with one customer to provide comprehensive early clinical support across an entire portfolio to build an alliance based on mutual...
Read More
Video
Dr. Nancy Dreyer discusses careers and opportunity in the epidemiology and outcomes team at Quintiles."Do you love epidemiology? Do you really enjoy practical solutions? Do you worry about continued research funding? If you answered yes, you need to check us...
Video
Adherence is a real challenge for the NHS and biopharma. It's not simply a case of patients remembering to take medicine that's an issue – it's the consequential effect upon NHS resources, and patients being able to achieve the outcomes that are associated with taking their medications. Biopharma needs to try and bridge this adherence gap through consistent and sustainable patient adherence strategies, responding to the individual motivations of each patient and understanding what factors affect patient adherence. If good patient adherence cannot be achieved, this will impact upon the collection of real world data required to make a compelling case to payers and clinicians to actually use their product. Payers and clinicians will be more inclined to go for an alternative product that...
Video
More and more, patients are playing an absolutely critical and pivotal role in their own health care. Previously patients may have been happy to receive information and support about their disease, the symptoms of it, and their treatment from their health care professional. But now patients are absolutely at the center of the care that they receive. Not only are they looking to their physicians for information and support about their treatments - but patients also looking for information themselves via both traditional and digital channels, such as the internet, patient support groups, and community groups. The key to an effective program that measurably improves patient engagement and adherence is gaining a comprehensive understanding of who a patient with that particular disease is –...
Fact Sheet
Safety can’t wait. That’s why we’re always ready. When you partner with Quintiles, our world-class cross-functional teams will deliver comprehensive patient safety solutions across your product’s lifecycle – from clinical to late-phase to real-world. Click on our infographic to learn about Quintiles' suite of integrated, comprehensive safety services and learn the importance of having a steady partner from start to finish, whatever your project needs and wherever you are in the product...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – August 5, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the closing of an underwritten, secondary public offering of 7,000,000 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation and Temasek Life Sciences Private Limited (the “Selling Shareholders”) at a price to the public of $77.85 per share.  The price per share paid to the Selling Shareholders by the underwriter was $77.37 per share.  Quintiles did not offer any stock in this transaction and did not receive any proceeds from the sale of the shares by the Selling Shareholders. Morgan Stanley served as the sole...
Read More
Fact Sheet
With new European medical device regulations on the horizon, including increased Notified Body involvement and heightened market surveillance, manufacturers face additional challenges to maintaining product CE Marking and bringing products to...
Read more
White Paper
This White Paper discusses and emphasizes the importance of ensuring the highest possible data retention rates in clinical outcome trials.  It presents a case study involving the TRILOGY Acute Coronary Syndromes clinical trial.  In collaboration with the Sponsor project team, Quintiles and Duke Clinical Research Institute developed and implemented a robust data retention process that led to a subject lost-to-follow-up rate of only 0.2% at study...
Explore More
Press Release
Research Triangle Park, NC – July 31, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the pricing of an underwritten, secondary public offering of 7,000,000 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation and Temasek Life Sciences Private Limited (the “Selling Shareholders”) at a price to the public of $77.85 per share. Quintiles will not receive any proceeds from the sale of the shares by the Selling Shareholders in this offering. Morgan Stanley is acting as the sole underwriter for this offering. The offering is expected to close on August 5, 2015, subject to customary closing conditions. An...
Read More
Press Release
Research Triangle Park, NC – July 30, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the launch of an underwritten, secondary public offering of 7,000,000 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation and Temasek Life Sciences Private Limited (the “Selling Shareholders”). Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders in the offering. Morgan Stanley is acting as the sole underwriter for this offering. An automatic shelf registration statement (including a prospectus) relating to the offering of...
Read More
Video
Jane Eisner, Senior Vice President, Customer Solutions Management Group, discusses the critical decisions facing Biopharma customers in developing their clinical pipelines and the benefits of working in collaboration to find the best end-to-end...